This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Xenetic Biosciences Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Xenetic Biosciences has a total shareholder equity of $12.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $13.7M and $856.4K respectively.

Belangrijke informatie

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio	n/a
Contant	US$11.99m
Aandelen	US$12.86m
Totaal verplichtingen	US$856.37k
Totaal activa	US$13.72m

Recente financiële gezondheidsupdates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: 3XB0's short term assets ($12.9M) exceed its short term liabilities ($856.4K).

Langlopende schulden: 3XB0 has no long term liabilities.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 3XB0 is debt free.

Schuld verminderen: 3XB0 had no debt 5 years ago.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 3XB0 has sufficient cash runway for more than a year based on its current free cash flow.

Voorspelling contante baan: 3XB0 has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 3.7% each year.

This company listing is no longer active

Xenetic Biosciences Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Xenetic Biosciences Receives a Non-Compliance Letter from Nasdaq

Xenetic Biosciences Receives Written Notification from the Listing Qualifications Department of the Nasdaq

Recent updates

Xenetic Biosciences, Inc. Announces the Appointment of James Parslow as Interim Chief Executive Officer

CLS Therapeutics Discloses its Views on Xenetic Biosciences

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform

Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023

First quarter 2023 earnings released: US$0.056 loss per share (vs US$0.12 loss in 1Q 2022)

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.55 loss in FY 2021)

Xenetic Biosciences, Inc., Annual General Meeting, Dec 21, 2022

Xenetic Biosciences Receives a Non-Compliance Letter from Nasdaq

Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board

Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.13 loss in 3Q 2021)

Xenetic Biosciences, Inc., Annual General Meeting, Dec 07, 2022

Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, Inc.

Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.13 loss in 2Q 2021)

Xenetic Biosciences Receives Written Notification from the Listing Qualifications Department of the Nasdaq

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1Q 2021)

Xenetic Biosciences, Inc. announced that it has received $0.86625 million in funding

High number of new directors

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$1.20 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.15 loss in 2Q 2020)

High number of new and inexperienced directors

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven